Prilenia Therapeutics
PrivateLast Round
Series B
Apr 12, 2022
Total Funding Raised
$180.5M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Prilenia Therapeutics operates in Healthcare & Life Sciences and is based in Naarden. Its latest recorded funding round was a Series B round in April 2022.
Prilenia Therapeutics is a biotechnology company that develops novel therapeutics to slow the progression of neurodegenerative and neurodevelopmental disorders, including Huntington's disease and amyotrophic lateral sclerosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prilenia Therapeutics Comparables
Compare Prilenia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| QurAlis | 81% | |
| Neurizon Therapeutics Limited | 80% | |
| NeuroSense Therapeutics | 78% |
For institutional investors. Book with your work email.
Prilenia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 12, 2022 | ||||
| Series B | Nov 3, 2021 | ||||
| Series A | Jun 3, 2020 | ||||
| Seed | Sep 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Prilenia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Series B |
| Forbion | Series B, Series A |
| Amplitude Ventures | Series B |
| Morningside Ventures | Series B, Series A |
| Genworks Health | Series A |
| ALS Investment Fund | Series B |
| Sectoral | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2026
Monthly visitors increased 60% MoM.
- May 1, 2026
Lead candidate pridopidine granted designation in U.S. and EU for HD and ALS.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 28, 2026
Prilenia presents new data and PREVAiLS study updates at the Northeast Amyotrophic Lateral Sclerosis (NEALS) Consortium 2026 annual meeting in Florida in 2026.
- attends_eventOct 28, 2026
Prilenia plans to share new pridopidine data and PREVAiLS study updates at the NEALS Consortium 2026 annual meeting in Florida in 2026.
- attends_eventOct 22, 2026
Prilenia is set to participate in the European Huntington's Disease Network (EHDN) Clinical Research Congress 2026 in Poland on Oct 22nd-24th '26, with its Chief Executive Officer giving an oral presentation and four posters being presented.
- hiresSep 8, 2026
Prilenia appoints Frederick "Rick" E. Munschauer III as chief medical officer to lead clinical development and evidence generation for its regulatory strategy as it advances the registrational Phase 3 PRECISE-HD and PREVAiLS studies in Huntington's disease and amyotrophic lateral sclerosis on Sep 8th '26.
- hiresSep 8, 2026
On Sep 8th '26, Prilenia appoints Frederick (Rick) E. Munschauer III, MD, as Chief Medical Officer to advance its work in Huntington's disease and amyotrophic lateral sclerosis.
For institutional investors. Book with your work email.
Prilenia Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Prilenia Therapeutics's valuation, stock price, and market status.
Is Prilenia Therapeutics a public or private company?
Prilenia Therapeutics is a private company.
What is the current stock price of Prilenia Therapeutics?
Prilenia Therapeutics is a private company, so its shares have no public market price. Caplight tracks Prilenia Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Prilenia Therapeutics worth (valuation)?
Valuation information for Prilenia Therapeutics is not publicly available.
Can I buy Prilenia Therapeutics stock?
Prilenia Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Prilenia Therapeutics's last funding round?
Prilenia Therapeutics's most recent funding round was Series B on April 12, 2022.
Who are the main investors in Prilenia Therapeutics?
Key investors in Prilenia Therapeutics include Forbion.
Will Prilenia Therapeutics IPO soon?
No public IPO plans have been announced for Prilenia Therapeutics.
How can I track Prilenia Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Prilenia Therapeutics's shares on secondary markets.